vs
艺达思集团（IEX）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
艺达思集团的季度营收约是Ultragenyx Pharmaceutical Inc.的1.9倍（$398.4M vs $207.3M），艺达思集团净利率更高（30.1% vs -62.0%，领先92.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 16.7%），艺达思集团自由现金流更多（$86.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -29.4%）
艺达思集团是一家公开上市的工业制造企业，专注于流体系统与特种工程产品的研发和生产，产品广泛应用于工业制造、生命科学、食品安全等多个领域，可为全球各行业客户提供高性能定制化解决方案。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
IEX vs RARE — 直观对比
营收规模更大
IEX
是对方的1.9倍
$207.3M
营收增速更快
RARE
高出9.2%
16.7%
净利率更高
IEX
高出92.1%
-62.0%
自由现金流更多
IEX
多$186.8M
$-100.8M
两年增速更快
RARE
近两年复合增速
-29.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $398.4M | $207.3M |
| 净利润 | $120.0M | $-128.6M |
| 毛利率 | 99.9% | — |
| 营业利润率 | 43.3% | -54.7% |
| 净利率 | 30.1% | -62.0% |
| 营收同比 | 16.7% | 25.9% |
| 净利润同比 | 25.7% | 3.5% |
| 每股收益（稀释后） | $1.61 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IEXRARE
| Q2 26 | $398.4M | — | ||
| Q1 26 | $407.7M | — | ||
| Q4 25 | $899.1M | $207.3M | ||
| Q3 25 | $878.7M | $159.9M | ||
| Q2 25 | $865.4M | $166.5M | ||
| Q1 25 | $814.3M | $139.3M | ||
| Q4 24 | $862.9M | $164.6M | ||
| Q3 24 | $798.2M | $139.5M |
净利润IEXRARE
| Q2 26 | $120.0M | — | ||
| Q1 26 | $128.3M | — | ||
| Q4 25 | $128.3M | $-128.6M | ||
| Q3 25 | $127.8M | $-180.4M | ||
| Q2 25 | $131.6M | $-115.0M | ||
| Q1 25 | $95.5M | $-151.1M | ||
| Q4 24 | $123.2M | $-133.2M | ||
| Q3 24 | $119.1M | $-133.5M |
毛利率IEXRARE
| Q2 26 | 99.9% | — | ||
| Q1 26 | 94.9% | — | ||
| Q4 25 | 43.1% | — | ||
| Q3 25 | 44.5% | — | ||
| Q2 25 | 45.3% | — | ||
| Q1 25 | 45.3% | — | ||
| Q4 24 | 42.5% | — | ||
| Q3 24 | 44.3% | — |
营业利润率IEXRARE
| Q2 26 | 43.3% | — | ||
| Q1 26 | 45.0% | — | ||
| Q4 25 | 20.4% | -54.7% | ||
| Q3 25 | 21.1% | -106.9% | ||
| Q2 25 | 21.7% | -64.8% | ||
| Q1 25 | 17.4% | -102.6% | ||
| Q4 24 | 19.2% | -74.3% | ||
| Q3 24 | 21.0% | -94.6% |
净利率IEXRARE
| Q2 26 | 30.1% | — | ||
| Q1 26 | 31.5% | — | ||
| Q4 25 | 14.3% | -62.0% | ||
| Q3 25 | 14.5% | -112.8% | ||
| Q2 25 | 15.2% | -69.0% | ||
| Q1 25 | 11.7% | -108.5% | ||
| Q4 24 | 14.3% | -80.9% | ||
| Q3 24 | 14.9% | -95.7% |
每股收益（稀释后）IEXRARE
| Q2 26 | $1.61 | — | ||
| Q1 26 | $1.71 | — | ||
| Q4 25 | $1.71 | $-1.28 | ||
| Q3 25 | $1.70 | $-1.81 | ||
| Q2 25 | $1.74 | $-1.17 | ||
| Q1 25 | $1.26 | $-1.57 | ||
| Q4 24 | $1.61 | $-1.34 | ||
| Q3 24 | $1.57 | $-1.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $586.2M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.0B | $-80.0M |
| 总资产 | $6.9B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IEXRARE
| Q2 26 | $586.2M | — | ||
| Q1 26 | $580.0M | — | ||
| Q4 25 | $580.0M | $421.0M | ||
| Q3 25 | $593.8M | $202.5M | ||
| Q2 25 | $568.2M | $176.3M | ||
| Q1 25 | $594.1M | $127.1M | ||
| Q4 24 | $620.8M | $174.0M | ||
| Q3 24 | $633.2M | $150.6M |
总债务IEXRARE
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.1B | — |
股东权益IEXRARE
| Q2 26 | $4.0B | — | ||
| Q1 26 | $4.0B | — | ||
| Q4 25 | $4.0B | $-80.0M | ||
| Q3 25 | $4.0B | $9.2M | ||
| Q2 25 | $4.0B | $151.3M | ||
| Q1 25 | $3.9B | $144.2M | ||
| Q4 24 | $3.8B | $255.0M | ||
| Q3 24 | $3.8B | $346.8M |
总资产IEXRARE
| Q2 26 | $6.9B | — | ||
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.9B | $1.5B | ||
| Q3 25 | $7.0B | $1.2B | ||
| Q2 25 | $6.9B | $1.3B | ||
| Q1 25 | $6.8B | $1.3B | ||
| Q4 24 | $6.7B | $1.5B | ||
| Q3 24 | $7.0B | $1.5B |
负债/权益比IEXRARE
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.46× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.55× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $86.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 21.6% | -48.6% |
| 资本支出强度资本支出/营收 | 4.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $654.3M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流IEXRARE
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $209.5M | $-99.8M | ||
| Q3 25 | $203.5M | $-91.4M | ||
| Q2 25 | $161.7M | $-108.3M | ||
| Q1 25 | $105.7M | $-166.5M | ||
| Q4 24 | $172.6M | $-79.3M | ||
| Q3 24 | $205.3M | $-67.0M |
自由现金流IEXRARE
| Q2 26 | $86.0M | — | ||
| Q1 26 | $189.8M | — | ||
| Q4 25 | $189.8M | $-100.8M | ||
| Q3 25 | $188.7M | $-92.7M | ||
| Q2 25 | $146.9M | $-110.7M | ||
| Q1 25 | $91.4M | $-167.8M | ||
| Q4 24 | $157.1M | $-79.5M | ||
| Q3 24 | $191.6M | $-68.6M |
自由现金流率IEXRARE
| Q2 26 | 21.6% | — | ||
| Q1 26 | 46.6% | — | ||
| Q4 25 | 21.1% | -48.6% | ||
| Q3 25 | 21.5% | -58.0% | ||
| Q2 25 | 17.0% | -66.5% | ||
| Q1 25 | 11.2% | -120.5% | ||
| Q4 24 | 18.2% | -48.3% | ||
| Q3 24 | 24.0% | -49.2% |
资本支出强度IEXRARE
| Q2 26 | 4.4% | — | ||
| Q1 26 | 15.6% | — | ||
| Q4 25 | 2.2% | 0.5% | ||
| Q3 25 | 1.7% | 0.8% | ||
| Q2 25 | 1.7% | 1.5% | ||
| Q1 25 | 1.8% | 1.0% | ||
| Q4 24 | 1.8% | 0.1% | ||
| Q3 24 | 1.7% | 1.2% |
现金转化率IEXRARE
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.63× | — | ||
| Q3 25 | 1.59× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.11× | — | ||
| Q4 24 | 1.40× | — | ||
| Q3 24 | 1.72× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IEX
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
